ArticleScience advances2024
Redirecting raltitrexed from cancer cell thymidylate synthase to
Open access · goldAbstract read
In one paragraph
Article in Science advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 7 citations in OpenAlex.
- MTHFD2: a promising metabolic checkpoint for diseases.Journal of translational medicine · 2026Review
- Diaryl-Aminoindazole with Extensive In Vitro Mycobactericidal Activity Dependent on Exposure to Reactive Nitrogen Species.ACS infectious diseases · 2026Article
- Thioquinazolinones as Antituberculosis Agents Targeting Phosphopantetheinyl Transferase.Journal of medicinal chemistry · 2025Article
- Targeting Siderophore Biosynthesis to Thwart Microbial Growth.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 9 institutions in 3 countries.
Amrita SinghDepartment of Microbiology and Immunology, Weill Cornell Medicine, New York, New York 10021, USA.ORCID 0000-0001-5649-8483
Samantha OttaviDivision of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0002-2238-7512
Inna KriegerDepartment of Biochemistry and Biophysics, Texas Agricultural and Mechanical University, College Station, TX 77843, USA.ORCID 0000-0001-7144-3069
Kyle PlanckDepartment of Medicine, Weill Cornell Medicine, New York, NY 10021, USA.ORCID 0000-0002-8496-2041
Andrew PerkowskiDivision of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0009-0000-1143-8962
Takushi KanekoGlobal Alliance for TB Drug Development, New York, NY 10005, USA.
Andrew M DavisDiscovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, UK.
Christine SuhDepartment of Microbiology and Immunology, Weill Cornell Medicine, New York, New York 10021, USA.ORCID 0009-0008-0912-6132
David ZhangDepartment of Microbiology and Immunology, Weill Cornell Medicine, New York, New York 10021, USA.
Laurent GoullieuxEvotec ID (Lyon), SAS 40 Avenue Tony Garnier, Lyon 69001, France.
Alexander AlexAMG Consultants Limited, Camburgh House, 27 New Dover Road, Canterbury, Kent, CT1 3DN, UK.
Christine RoubertEvotec ID (Lyon), SAS 40 Avenue Tony Garnier, Lyon 69001, France.
Mark GardnerAMG Consultants Limited, Camburgh House, 27 New Dover Road, Canterbury, Kent, CT1 3DN, UK.
Marian PrestonDiscovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, UK.
Dave M SmithDiscovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, UK.ORCID 0000-0001-6831-280X
Yan LingDepartment of Microbiology and Immunology, Weill Cornell Medicine, New York, New York 10021, USA.ORCID 0000-0002-5155-9766
Julia RobertsDepartment of Microbiology and Immunology, Weill Cornell Medicine, New York, New York 10021, USA.
Bastien CautainEvotec ID (Lyon), SAS 40 Avenue Tony Garnier, Lyon 69001, France.
Anna UptonEvotec ID (Lyon), SAS 40 Avenue Tony Garnier, Lyon 69001, France.ORCID 0000-0002-9522-1230
Christopher B CooperGlobal Alliance for TB Drug Development, New York, NY 10005, USA.ORCID 0000-0002-2631-6818
Natalya SerbinaGlobal Alliance for TB Drug Development, New York, NY 10005, USA.ORCID 0009-0007-2303-9468
Zaid TanvirGlobal Alliance for TB Drug Development, New York, NY 10005, USA.
John MosiorDepartment of Biochemistry and Biophysics, Texas Agricultural and Mechanical University, College Station, TX 77843, USA.ORCID 0000-0002-5649-7824
Ouathek OuerfelliOrganic Synthesis Core, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-7038-0219
Guangli YangOrganic Synthesis Core, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-5097-5266
Ben S GoldDepartment of Microbiology and Immunology, Weill Cornell Medicine, New York, New York 10021, USA.ORCID 0000-0002-9562-8241
Kyu Y RheeDepartment of Medicine, Weill Cornell Medicine, New York, NY 10021, USA.ORCID 0000-0003-4582-2895
James C SacchettiniDepartment of Biochemistry and Biophysics, Texas Agricultural and Mechanical University, College Station, TX 77843, USA.ORCID 0000-0001-5767-2367
Nader FotouhiGlobal Alliance for TB Drug Development, New York, NY 10005, USA.ORCID 0009-0001-9314-1704
Jeffrey AubéDivision of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0003-1049-5767
Carl NathanDepartment of Microbiology and Immunology, Weill Cornell Medicine, New York, New York 10021, USA.ORCID 0000-0002-7744-8896
Cornell University · USTB Alliance · USEvotec (United States) · USAstraZeneca (United Kingdom) · GBTexas College · USUniversity of North Carolina at Chapel Hill · USMemorial Sloan Kettering Cancer Center · USQueen Mary University of London · GBUniversity of Kent · GB
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MVulnerabilities in Mycobacterial Cell-Wall BiogenesisP01AI095208 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI RUBIN, ERIC J. · 2012 to 2022
$19.8MStudy of M. tuberculosis under human host selection to identify virulence and barrier lipids (Project 1)U19AI162584 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI WOOD, ROBIN · 2021 to 2025
$13.5MDiscovery of Phospopantetheinyl Transferse Inhibitors Against Mycobacterium tuberculosisR01AI155510 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI AUBE, JEFFREY · 2021 to 2024
$3.1MOrganic Synthesis at the Service of Biology and MedicineR50CA243895 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Ouathek Ouerfelli · 2019 to 2026
$1.9MMetabolic Impact of Tryptophan Synthase Inhibition in Mycobacterium tuberculosis and Implications for Rational Combination TherapyF31AI154832 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI PLANCK, KYLE · 2020 to 2022
$138kGates Foundation INV-002431Gates Foundation INV-004709NCI NIH HHS P30 CA008748NCI NIH HHS R50 CA243895NIAID NIH HHS F31 AI154832NIAID NIH HHS P01 AI095208NIAID NIH HHS R01 AI155510NIAID NIH HHS U19 AI162584
Abstract
There is a compelling need to find drugs active against
Indexed as
Mycobacterium tuberculosisNeoplasmsQuinazolinesThiophenesTransferases (Other Substituted Phosphate Groups)Bacterial ProteinsHumansThymidylate SynthaseBacterial Proteinsphosphopantetheinyl transferaseQuinazolinesraltitrexedThiophenesThymidylate SynthaseTransferases (Other Substituted Phosphate Groups)
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.